<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765440</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000599477</org_study_id>
    <nct_id>NCT00765440</nct_id>
  </id_info>
  <brief_title>Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract</brief_title>
  <official_title>Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: It is not yet known which regimen of enteral nutrition is more effective in&#xD;
      preventing infections in patients undergoing surgery for cancer of the upper aerodigestive&#xD;
      tract.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is comparing three nutrition regimens in treating&#xD;
      patients with cancer of the upper aerodigestive tract.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of immunonutrition (IMPACT®) in patients with de novo cancer of&#xD;
           the upper aerodigestive tract.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the best time to initiate treatment.&#xD;
&#xD;
        -  Compare the intermediate duration of treatment.&#xD;
&#xD;
        -  Compare nutritional parameters.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days&#xD;
           prior to surgery and over 7 days after surgery.&#xD;
&#xD;
        -  Arm II: Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior&#xD;
           to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after&#xD;
           surgery.&#xD;
&#xD;
        -  Arm III: Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery&#xD;
           and enteral adjuvant IMPACT® nutrition over 7 days after surgery.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 30 days after surgery and then at&#xD;
      2 and 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of infectious complication</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Infection</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>therapeutic nutritional supplementation</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of de novo cancer of the upper aerodigestive tract, including the following:&#xD;
&#xD;
               -  Oral cavity&#xD;
&#xD;
               -  Larynx&#xD;
&#xD;
               -  Oropharynx&#xD;
&#xD;
               -  Hypopharynx&#xD;
&#xD;
          -  Planned surgical excision of tumors with opening of the mucous membranes, with or&#xD;
             without immediate reconstruction by myocutaneous pedicle flap or free-bone graft&#xD;
&#xD;
          -  Planned adjuvant enteral nutritional regimen lasting at least 7 days post-operatively&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ANC &gt; 1.8 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Transaminases ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 3 times ULN&#xD;
&#xD;
          -  Creatinine 70-250 μmol/L&#xD;
&#xD;
          -  Urea ≤ 1.5 times ULN&#xD;
&#xD;
          -  Glucose &lt; 1.5 g/L&#xD;
&#xD;
          -  Sodium &lt; 145 mmol/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No psychological, social, geographical, or familial reasons prohibiting follow-up&#xD;
&#xD;
          -  No insulin-dependent diabetes&#xD;
&#xD;
          -  No severe psychiatric illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No head and neck surgery for cancer within the past year&#xD;
&#xD;
          -  No prior oral components of immunonutrition&#xD;
&#xD;
          -  No prior neoadjuvant chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy to head and neck&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Noelle Falewee Pastor</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>malnutrition</keyword>
  <keyword>stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

